Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
Recruiting
Early Phase 1
Interventional Study
Lymphedema
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 110 (estimated)
- Sponsor
- Advanced Reconstructive Surgery Alliance · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to eva…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Adults 18 years or older with unilateral upper or lower extremity lymphedema Limb volume \> 5% BMI =\> 23 Oncology clearance if there is a cancer history
Exclusion Criteria:
Moderate to severe venous insufficiency Actively using GLP-1 RAs Known intolerance or adverse effect to…
Contacts